Programmed cell death 5 mediates HDAC3 decay to promote genotoxic stress response

Hyo-Kyoung Choi1,*, Youngsok Choi2,*, Eun Sung Park3,*, Soo-Yeon Lee1, Jaesung Seo1, Mi-Hyeon Jeong1, Jae-Wook Jeong4, Jae-Ho Cheong5, Peter C.W. Lee6, Kyung-Chul Choi6 & Ho-Geun Yoon1

The inhibition of p53 activity by histone deacetylase 3 (HDAC3) has been reported, but the precise molecular mechanism is unknown. Here we show that programmed cell death 5 (PDCD5) selectively mediates HDAC3 dissociation from p53, which induces HDAC3 cleavage and ubiquitin-dependent proteasomal degradation. Casein kinase 2 alpha phosphorylates PDCD5 at Ser-119 to enhance its stability and importin 13-mediated nuclear translocation of PDCD5. Genetic deletion of PDCD5 abrogates etoposide (ET)-induced p53 stabilization and HDAC3 cleavage, indicating an essential role of PDCD5 in p53 activation. Restoration of PDCD5WT in PDCD5−/− MEFs restores ET-induced HDAC3 cleavage. Reduction of both PDCD5 and p53, but not reduction of either protein alone, significantly enhances in vivo tumorigenicity of AGS gastric cancer cells and correlates with poor prognosis in gastric cancer patients. Our results define a mechanism for p53 activation via PDCD5-dependent HDAC3 decay under genotoxic stress conditions.
eciphering the regulatory pathway for p53-dependent apoptosis, which is involved in a variety of stress signals, is important for understanding tumorigenesis and paving the way for new cancer therapies. In response to a broad range of cellular stresses, p53 accumulates in the cell and thereby becomes activated, indicating that protein abundance dictates function. It is generally believed that p53 protein accumulation is not due to an enhanced transcriptional response of the cell, but rather is the consequence of p53 protein stabilization resulting from post-translational modifications. Acetylation of p53 at different lysine residues has been shown to produce a variety of effects on p53 function. For example, acetylation-dependent p53 stabilization was shown to antagonize the mouse double minute 2 homology (MDM2)-mediated negative control of p53. Conversely, deacetylation of p53, either by an HDAC1-containing complex or by the NAD-dependent histone deacetylase Sir2a, was shown to repress p53-dependent transcriptional activation, apoptosis and growth arrest. MDM2 was also shown to interfere with the acetylation of p53, and subsequently promote the HDAC1-mediated deacetylation of p53. Thus, coordinated interplay between histone acetyltransferases and histone deacetylases (HDACs) in the regulation of p53 acetylation is believed to play a significant role in p53-mediated apoptosis.

Recent studies highlight a connection between HDAC3 function and p53-mediated apoptosis. For instance, suppression of HDAC3 expression, or inhibition of its activity, was found to increase p53 stability and acetylation in human cancer cells. Moreover, HDAC3 and p53 have been shown to interact indirectly via formation of a complex with the MAGE-A tumour antigen, which confers resistance to chemotherapeutic agents. In accordance with the above finding, downregulation of HDAC3 decreases cancer cell death in response to anticancer drugs. Stimuli such as osmotic stress or FAS ligand binding trigger the caspase-7-dependent C-terminal cleavage of HDAC3 in mammalian cells, eventually leading to apoptosis induction by modulation of HDAC3 activity. Although these studies demonstrated the potential engagement of HDAC3 in caspase-7-dependent apoptosis, the effects of caspase-7-mediated cleavage on HDAC3 deacetylase activity are somewhat controversial. These findings suggest that apoptotic stimuli may alter the function of HDAC3 via C-terminal cleavage, presumably by leading to cellular apoptosis via activation of a pro-apoptotic molecule such as p53. Consistent with this hypothesis, a meta-analysis of human solid tumours showed that HDAC3 was one of the most frequently upregulated genes in cancer cells. This suggests that cancer cells may resist apoptotic cell death, at least in part, through HDAC3-mediated mechanisms. However, detailed mechanisms underlying the role of HDAC3 in p53-mediated apoptosis have not been fully elucidated.

Programmed cell death 5 (PDCD5), also designated TFAR19, is a novel gene from TF-1 cells undergoing cytokine deprivation-induced apoptosis. The amino-acid sequence of PDCD5 is quite conserved among eukaryotic species, indicating that PDCD5 has important biological functions in multiple organisms. PDCD5 is widely expressed in a variety of tissues, with messenger RNA (mRNA) levels in fetal tissue being significantly lower than that observed in adult tissues. Accumulating evidence indicates that expression of PDCD5 is downregulated in human cancer patients, specifically those affected by lung cancer, ovarian cancer, gastric cancer and glioma, suggesting that decreased expression of PDCD5 may be associated with the pathogenesis of human tumours. When overexpressed in cancer cell lines, PDCD5 facilitates apoptosis triggered by genotoxic stress. PDCD5 protein is accumulated in cells undergoing apoptosis, and translocates rapidly from the cytoplasm to the nucleus of cells. Recent studies also show that PDCD5 plays an important enhancing role in TAJ/TROY-triggered paraptosis-like cell death.

In this study, we demonstrate that PDCD5 promotes genotoxic stress-induced p53 acetylation through direct mediating dissociation of HDAC3 from p53, leading to caspase-3-dependent HDAC3 cleavage. Furthermore, we reveal that PDCD5 is required for p53 stabilization and cleavage of HDAC3 in vivo. Finally, we verify the positive correlation between PDCD5 and p53 in human gastric cancer patients and in vivo tumorigenicity of gastric cancer cells. Our findings highlight the functional importance of PDCD5 in genotoxic stress-induced p53 activation through its HDAC3 decay-mediating activity.

**Results**

PDCD5 induces caspase-3-mediated cleavage of HDAC3. To better understand the functional role of HDAC3 in apoptotic signalling, we performed the yeast two-hybrid screen using human testis, ovary and breast tissue libraries and identified 23 HDAC3-interacting proteins (Supplementary Table 1). Among the identified proteins, PDCD5, a tumour suppressor that was recently found to act as a pro-apoptotic factor, was particularly interesting and thus selected for this study. Moreover, we detected HDAC3 in an immunopurified PDCD5 complex with a high confidence using liquid chromatography–mass spectrometry (MS/MS) analysis, suggesting an in vivo interaction between HDAC3 and PDCD5 (Supplementary Table 2). Endogenous co-immunoprecipitation analysis demonstrated that PDCD5 selectively interacts with HDAC3 among class I HDACs. Reciprocally, PDCD5 selectively binds to and mediates caspase-3-dependent cleavage of HDAC3 at Asp-391.
HDAC3 specifically interacted with PDCD5 among PDCD proteins, which are known to be involved in apoptotic signalling. These results indicate that HDAC3, among class I HDACs, is a unique PDCD5-associating protein (Fig. 1a). Same results were also obtained with A2780 ovarian cancer cells (Supplementary Fig. 1a,b). Mapping analysis showed that the N-terminal domain of PDCD5 (1–30 amino acids (a.a.)) directly interacts with the N-terminal domain (1–106 a.a.) of HDAC3 (Supplementary Fig. 1c,d).

The C-terminal cleavage of HDAC3 at Asp-391 was reported to be important for cellular stress-induced apoptosis11,12. Moreover, PDCD5 has been shown to induce apoptotic cell death and upregulate expression of genes involved in apoptosis15,21. Thus, we first explored the possibility of PDCD5 involvement in C-terminal cleavage of HDAC3. Importantly, overexpression of PDCD5, but not PDCD4 or PDCD6, selectively induced cleavage of HDAC3, among class I HDACs, indicating the exclusive role of PDCD5 in the C-terminal cleavage of HDAC3 (Fig. 1b,c). To verify in vivo cleavage of HDAC3 by PDCD5, a proximity ligation assay (PLA) was performed25 using a double-labeled HDAC3 construct (Flag-HDAC3-3HA). Overexpression of PDCD5, but not PDCD4 or PDCD6, efficiently induced the cleavage of HDAC3 (Fig. 1d). As expected, PDCD5 induced the cleavage of wild-type but not mutant HDAC3391A (Fig. 1e, right panel).

As caspase-7 has been reported to be an executioner for HDAC3 cleavage during osmotic stress11, we next examined whether caspase-7 is also required for PDCD5-mediated HDAC3 cleavage. As expected, treatment with the pan-caspase inhibitor, Z-VAD, abrogated PDCD5-mediated HDAC3 cleavage. Unexpectedly, treatment with the caspase-3-specific inhibitor, Z-DQMD, unexpectedly blocked PDCD5-mediated HDAC3 cleavage (Fig. 1f). Furthermore, inhibition of caspase-7 had no effects on the HDAC3 cleavage by ET treatment (Fig. 1g; Supplementary Fig. 3). ET treatment efficiently induced HDAC3 cleavage in HCT-116 (p53+/+) cells; however, PDCD5 knockdown inhibited ET-induced HDAC3 cleavage, suggesting that interaction with PDCD5 is required for HDAC3 cleavage (Fig. 1e, left panel and Supplementary Fig. 2). Because Asp-391 of HDAC3 is known to be a conserved cleavage site, we next investigated whether this site is a target for PDCD5-mediated cleavage. As expected, PDCD5 induced the cleavage of wild-type but not mutant HDAC3391A (Fig. 1e, right panel).

As caspase-7 has been reported to be an executioner for HDAC3 cleavage during osmotic stress11, we next examined whether caspase-7 is also required for PDCD5-mediated HDAC3 cleavage. As expected, treatment with the pan-caspase inhibitor, Z-VAD, abrogated PDCD5-mediated HDAC3 cleavage. Unexpectedly, treatment with the caspase-3-specific inhibitor, Z-DQMD, unexpectedly blocked PDCD5-mediated HDAC3 cleavage (Fig. 1f). Furthermore, inhibition of caspase-7 had no effects on the HDAC3 cleavage by ET treatment (Fig. 1g; Supplementary Fig. 3). ET treatment efficiently induced HDAC3 cleavage in HCT-116 (p53+/+) cells; however, PDCD5 knockdown inhibited ET-induced HDAC3 cleavage, suggesting PDCD5 mediates ET-induced HDAC3 cleavage (Fig. 1h). These collectively demonstrated that PDCD5 induces caspase-3-mediated HDAC3 cleavage in response to ET.

PDCD5 stabilizes p53 by inhibiting HDAC3–p53 interactions. Given results suggesting PDCD5 is involved in caspase-3-dependent HDAC3 cleavage, we next investigated the role of PDCD5 in regulation of HDAC3 function. Because HDAC activity is known to be a critical function of HDAC3 (ref. 26), we first assessed the change in HDAC3 activity after either overexpression or depletion of PDCD5 in cells. An increase in wild-type PDCD5 expression, but not mutant PDCD5148R, resulted in a decrease of HDAC3 histone deacetylase activity (Fig. 2a). However, overexpression of either PDCD4 or PDCD6 had no effect on HDAC3 histone deacetylase activity (Supplementary Fig. 4). Conversely, PDCD5 knockdown inhibited ET-induced reduction of HDAC3 activity, indicating that PDCD5 selectively mediates ET-induced effects on HDAC3 (Fig. 2b).

Next, we examined the molecular basis of PDCD5 involvement in ET-induced HDAC3 cleavage and inhibition. ET treatment of cells markedly increased the interaction between HDAC3 and active caspase-3. However, knockdown of PDCD5 levels abrogated this enhanced association (Fig. 2c). Importantly, while ET treatment induced cytoplasmic accumulation of cleaved HDAC3, knockdown of PDCD5 abolished this ET-induced cleavage (Fig. 2d; Supplementary Fig. 5a). Conversely, ET treatment of cells overexpressing wild-type PDCD5 further enhanced the cytoplasmic accumulation of HDAC3 (Fig. 2e). These data collectively demonstrate that ET triggers nuclear translocation of PDCD5, which in turn induces nuclear export of HDAC3 and caspase-3-mediated HDAC3 cleavage.

Acetylation and stability of p53 is coordinated by histone acetyltransferases and HDAC27. Among HDACs, HDAC3 was recently shown to interact with p53 through MAGE-A2. Thus, we hypothesized that nuclear PDCD5 induces dissociation of HDAC3 from p53, subsequently triggering the cytoplasmic translocation and caspase-3-dependent cleavage of HDAC3, in turn increasing the acetylation level of p53. Results from co-immunoprecipitation analyses showed ET treatment efficiently induced the removal of HDAC3 from p53 and concomitant association of p300 with p53. However, knockdown of PDCD5 abolished ET-induced HDAC3–p53 dissociation, and also decreased p53 acetylation and stability (Fig. 2f; Supplementary Fig. 5b). Intriguingly, we found that both HDAC3 and PDCD5 bind to the same region of p53 (100–170 a.a.) (Supplementary Fig. 6). An in vitro pull-down and deacetylation assay showed that HDAC3 directly binds to and deacetylates p53 (Supplementary Fig. 7a,b). An in vitro competition assay demonstrated that wild-type PDCD5, but not the point mutant PDCD5E16D that has defective interaction with p53, competitively inhibited HDAC3 binding to p53 (Supplementary Figs 2 and 7c). Consistently, PDCD5E16D overexpression did not affect HDAC3–p53 interaction or HDAC3 cleavage compared with that of PDCD5WT (Fig. 2g). Unexpectedly, MAGE-A2 knockdown in both H1299 and HCT-116 (p53–/−) cells had negligible effect
lysates were immunoblotted with the indicated antibodies. Overexpression of HDAC3WT, but not the inactive HDAC3Y298F mutant, efficiently reduced p53 acetylation independently of MDM2 (Fig. 3c). These results suggest that the PDCD5–HDAC3 network regulates p53 stabilization independently of MDM2 and MAGE-A2. Both cycloheximide treatment and ET time-course experiments verified that PDCD5 mediates HDAC3 degradation and p53 acetylation in response to genotoxic stress (Fig. 2h,i). Collectively, these results suggest that PDCD5 stabilizes p53 by inhibiting HDAC3–p53 interactions, which leads to translocation of HDAC3 from the nucleus to the cytosol and subsequent caspase-3-dependent cleavage.

PDCD5 induces cleavage and degradation of HDAC3. HDAC3 cleavage by PDCD5 correlates with increased p53 acetylation; however, HDAC3 cleavage is not observed during ET treatment at the time (4 h) when p53 is activated. We next examined whether the cleaved form of HDAC3 was rapidly degraded during ET treatment. At 2 h after the start of ET treatment, p53 acetylation at multiple lysine residues increased when the cleavage of HDAC3 was observed in the presence of MG132 (Supplementary Fig. 9a). At 4 h after the start of ET treatment, ~20% of HDAC3 was observed as the cleaved form in the presence of MG132. At 12 h after the start of ET treatment, we found that ~60% of full-length HDAC3 in the cell lysate was cleaved and dissociated from p53, which is consistent with maximum p53 activation (Fig. 3a). However, PDCD5 knockdown strongly reduced the percentage of HDAC3 cleavage and the dissociation of HDAC3 from p53 in response to ET treatment (Fig. 3b; Supplementary Fig. 9a). Similar results were observed by PDCD5 overexpression in the presence of MG132 (Supplementary Fig. 9b). We found that ET treatment induced the time-dependent ubiquitination and cleavage of HDAC3 (Fig. 3c); however, depletion of PDCD5 substantially reduced HDAC3 ubiquitination (Fig. 3d). By contrast, uncleaved mutant HDAC3D391A was not ubiquitinated in response to ET treatment (Fig. 3e). Confocal microscopy analysis showed the nuclear retention of uncleaved HDAC3D391A even after ET treatment, suggesting that cytoplasmic translocation and cleavage of HDAC3 is required for HDAC3 ubiquitination (Supplementary Fig. 9c). Moreover, HDAC3D391A overexpression conferred stronger inhibition of PDCD5-induced p53 acetylation and activation that was conferred by HDAC3WT (Fig. 3f). These results indicate that PDCD5 induces caspase-3-dependent HDAC3 cleavage, which leads to ubiquitin-dependent proteasomal degradation of HDAC3.

**Figure 3** | PDCD5 mediates ubiquitin-dependent proteasomal degradation of HDAC3 via C-terminal cleavage of HDAC3. (a) MG132 treatment induces accumulation of cleaved HDAC3. Cells were treated with ET (50 μM) and/or MG132 (10 μM, 3 h). Whole-cell lysates were immunoblotted with the indicated antibodies. Arrow indicates cleaved HDAC3 (left panel). Intensities of protein bands obtained from the immunoblotting assay were quantified with ImageJ (right panel) and normalized with respect to that of intensities from both cleaved and full-length HDAC3. Error bars, s.d. (n = 3). (*P < 0.01 versus without ET.) (b) PDCD5 knockdown diminishes the reduction and cleavage of full-length HDAC3. shPDCD5-expressing HCT-116 cells were treated with ET and/or MG132. Whole-cell lysates were immunoprecipitated and immunoblotted with the indicated antibodies (left panel). Relative % intensity was calculated as described above (right panel). Error bars, s.d. (n = 3). (*P < 0.01 versus without ET.) (c) HDAC3 ubiquitination increases in a time-dependent manner in response to ET treatment. Cells were transfected with HA-Ub plasmid and treated with MG132 and/or ET. Whole-cell lysates were immunoprecipitated with anti-HDAC3 (C) antibody and immunoblotted with the indicated antibodies. (d) PDCD5 knockdown diminishes HDAC3 ubiquitination in response to ET. Whole-cell lysates were immunoprecipitated with anti-HDAC3 (C) antibody and immunoblotted with the indicated antibodies. (e) Mutation of Asp-391 abolishes ET-induced HDAC3 ubiquitination. Cells were transfected with HA-Ub and the indicated Flag-tagged plasmids, and treated with ET and/or MG132. Whole-cell lysates were immunoprecipitated with anti-Flag antibody and immunoblotted with the indicated antibodies. (f) Mutation of Asp-391 potentiates the action of HDAC3 in the inhibition of PDCD5-mediated p53 acetylation. Cells were transfected with the indicated Flag-tagged plasmids. Whole-cell lysates were immunoblotted with the indicated antibodies.

**CK2ζ-mediated phosphorylation enhances PDCD5 stabilization.** We next examined how PDCD5 levels are increased and how PDCD5 is translocated into the nucleus in response to ET treatment. CK2ζ phosphorylated PDCD5 at Ser-119; mutation of this site disrupted the pro-apoptotic function of PDCD5 (ref. 29). Therefore, we tested whether CK2ζ-mediated phosphorylation increased PDCD5 stability. Treatment with MG132 significantly increased PDCD5 levels, whereas CK2ζ knockdown diminished the effect of MG132 on PDCD5 stabilization (Fig. 4a). A cycloheximide time-course experiment showed that CK2ζ enhanced PDCD5 stability. CK2ζ knockdown reduced PDCD5 stability, indicating a crucial role for CK2ζ in PDCD5 stabilization (Supplementary Fig. 10a). To confirm these results, we generated a PDCD5 antibody that specifically recognized the phosphorylated Ser-119 residue. The phospho-specific antibody detected phosphorylated Ser-119 in PDCD5WT, but not in the PDCD5S119A mutant, verifying its specificity (Supplementary Fig. 10b). We observed that the levels of both PDCD5 and phosphorylated PDCD5 concurrently increase in response to ET treatment. However, CK2ζ knockdown diminished the levels of PDCD5 and phosphorylated PDCD5, and reduced HDAC3 cleavage and p53 activation in response to ET (Fig. 4b; Supplementary Fig. 10c). CK2ζ overexpression markedly reduced PDCD5 ubiquitination (Fig. 4c) and increased PDCD5 stability, but not PDCD5 mRNA levels (Supplementary Fig. 10d). These results indicate that CK2ζ-mediated phosphorylation of Ser-119 is required for PDCD5 stabilization.

**IPO13 mediates nuclear translocation of phospho-PDCD5.** We examined how PDCD5 is translocated into the nucleus in response to ET treatment. First, we performed bioinformatics analysis to search for nuclear localization signals (NLSs) in PDCD5, and identified a candidate NLS sequence in the N-terminal (1–20 a.a.) region. Then, we used site-directed mutagenesis to generate several different PDCD5 point mutants. Each PDCD5 point mutant was transfected into HCT-116 cells, and nuclear translocation was examined by confocal microscopy. Mutation of the candidate NLS sequence had no effect on PDCD5 subcellular localization in response to ET treatment (Supplementary Fig. 11a). However, mutation of the Ser-119 residue blocked PDCD5 translocation into the nucleus that was observed with wild-type PDCD5. Strikingly, the phospho-

---

**ARTICLE**

NATURE COMMUNICATIONS | DOI: 10.1038/ncomms8390 | www.nature.com/naturecommunications

© 2015 Macmillan Publishers Limited. All rights reserved.
mimetic PDCD5 mutant (PDCD5S119D) localized primarily in the nucleus even without ET treatment, suggesting that CK2-mediated phosphorylation of Ser-119 is required for nuclear translocation of PDCD5 in response to genotoxic stress (Fig. 4d). Cell fractionation analysis again verified the above finding that phosphor-PDCD5 rapidly moved into nucleus upon ET treatment. However, knockdown of CK2α blocked the nuclear localization of PDCD5 (Supplementary Fig. 11b,c). There are evidences that phosphorylation activates non-canonical transport signals and the phosphorylated motif is recognized by nuclear receptor importin-β family without intervention of an importin-α-like protein30. Strikingly, we found that PDCD5 selectively binds to a nuclear transport protein IPO13 in response to ET, and the knockdown of IPO13 abrogated the nuclear translocation of
endogenous PDCD5 (Fig. 4e,f; Supplementary Fig. 11d). Importantly, knockdown of IPO13 abolished the nuclear retention of phospho-mimetic PDCD5S119D mutant (Fig. 4g). Moreover, IPO13 strongly binds to phospho-mimetic PDCD5S119D but not with the phospho-mutant PDCD5S119A, indicating that IPO13 is indispensable for nuclear translocation of phospho-PDCD5 (Supplementary Fig. 11f). Finally, overexpression of PDCD5S119D induced HDAC3 cleavage and p53 activation more strongly than that induced by wild-type PDCD5. By contrast, the phospho-mutant PDCD5S119A had no effect on HDAC3 cleavage and p53 activation (Fig. 4h). Collectively, these results demonstrate that CK2-dependent phosphorylation is required for IPO13-mediated nuclear translocation of PDCD5, which leads to HDAC3 cleavage in response to ET treatment.

PDCD5 promotes p53 function via HDAC3 inhibition. To investigate the functional significance of PDCD5-mediated HDAC3 cleavage on p53-dependent apoptosis, we observed the modulation of pro-apoptotic genes after knocking down or overexpressing PDCD5 and/or HDAC3. PDCD5 knockdown abrogated both ET- and staurosporine (STS)-induced transcription of p53-target genes, Puma and Bax. Accordingly, overexpression of PDCD5 further enhanced ET-induced p53-target gene expression. Strikingly, coexpression of both PDCD5 and HDAC3 attenuated the positive action of PDCD5 on ET-induced p53-target gene expression, indicating an antagonistic function of HDAC3 in PDCD5-mediated apoptosis (Fig. 5a).

Next, we examined whether the pro-apoptotic function of PDCD5 is dependent on p53. Overexpression of PDCD5 in HCT-116 (p53+/−) cells yielded a significant increase in annexin V-positive cells compared with HCT-116 (p53−/−). Moreover, both inhibition and knockdown of caspase-3 fully abrogated PDCD5-enhanced apoptotic cell death in HCT-116 (p53+/−) cells, but not in HCT-116 (p53−/−), suggesting that PDCD5 promotes genotoxic stress-induced apoptosis in a p53-dependent manner (Fig. 5b; Supplementary Fig. 12a). Strikingly, overexpression of HDAC3 selectively antagonized PDCD5-mediated apoptosis, indicating the exclusive role of HDAC3 in PDCD5-mediated apoptotic signalling (Fig. 5c; Supplementary Fig. 12b). Although depletion of class I HDACs commonly enhanced ET-induced apoptosis, likely due to their activity in genome maintenance, depletion of HDAC3 further enhanced ET-induced apoptosis of HCT-116 (p53+/−) cells than that induced by other HDACs (Fig. 5d). Collectively, these data indicate that PDCD5 negatively regulates anti-apoptotic action of HDAC3 in a p53-dependent manner.

PDCD5 mediates acetylation-dependent p53 stabilization. Our results illustrating the p53-dependent action of PDCD5 in genotoxic stress responses led us to further investigate whether PDCD5 is critical for the stabilization and activation of p53. For this, we generated PDCD5−/− MEFs from wild-type mice (Supplementary Fig. 14). MEFs generated from these mice were subjected to a Cre recombinase (Ad-Cre)-expressing adenovirus to delete PDCD5, generating a PDCD5−/− MEF line. Ad-Cre recombinase treatment depleted most PDCD5 protein in MEFs derived from PDCD5+/− mice (Fig. 6a). Depletion of PDCD5 strongly reduced HDAC3 cleavage and p53 activation in response to ET treatment and p53 overexpression (Fig. 6a; Supplementary Fig. 15a). Consistently, a Mdm2 inhibitor, nutlin3a treatments had negligible effects on HDAC3 cleavage and p53 activation in PDCD5−/− MEFs (Supplementary Fig. 15b). However, rescue of PDCD5−/− MEFs with haemagglutinin (HA)-tagged PDCD5 WT, but not with PDCD5E16D, markedly increased p53 activity, HDAC3 cleavage and transcription of the p53−p300 complex to the p53−RE of Bax and Puma, indicating that PDCD5 is required for p53 activation via HDAC3 cleavage (Fig. 6b,c; Supplementary Figs 13b and 15b,c). Importantly, rescue of PDCD5-knockdown p53−/−
MEFs with p53 and wild-type PDCD5\(^{WT}\), but not mutant PDCD5\(^{E16D}\), resulted in regained p53 action on ET-induced HDAC3 cleavage, target gene expression and apoptosis (Fig. 6d; Supplementary Fig. 15d). These results again verify that PDCD5 and p53 are mutually required for genotoxic stress-induced apoptosis and HDAC3 cleavage. We observed that HDAC3 knockdown rescued p53 suppression caused by PDCD5 depletion (Fig. 6e; lane 3 versus 4). Restoration of PDCD5\(^{WT}\), but
not PDCD5<sup>E16D</sup>, further enhanced the effect of HDAC3 knockdown on p53 acetylation and activation (lane 2 versus 5), again confirming the crucial role of PDCD5 in acetylation-induced p53 stabilization (Fig. 6e; Supplementary Fig. 15e). Notably, overexpression of uncleaved mutant HDAC3<sup>D391A</sup> markedly suppressed ET-induced p53 acetylation and activation, as well as apoptosis, when compared with wild-type HDAC3<sup>WT</sup>. As expected, the cleaved form of HDAC3 (HDAC3<sup>1–391</sup>) had negligible effects on both p53 activation and apoptosis, supporting our notion that HDAC3 function is negatively regulated during genotoxic stress responses (Fig. 6f; Supplementary Figs 13c and 15f).

To further corroborate the critical role of PDCD5 in genotoxic stress-induced DNA damage in vivo, PDCD5<sup>−/−</sup> mice were treated with ET followed by injection of adenovirus for green fluorescent protein (GFP) or Cre recombinase to ablate PDCD5 mRNA expression in liver. ET injection significantly induced the HDAC3 cleavage and levels of p53 at 1 and 2 days when compared without ET injection. However, depletion of PDCD5 markedly diminished HDAC3 cleavage and levels of p53. As expected, the mRNA levels of Puma and p21 were not increased in the depletion of PDCD5 (Fig. 6g). Collectively, these data demonstrate that PDCD5 plays an essential role in p53 activation by modulating the decay of HDAC3 in vivo.

Reduction of PDCD5 and p53 enhances gastric tumorigenesis

Reduced expression of PDCD5 has been reported in patients with multiple cancer types including gastric, lung, ovarian and glioma<sup>16–18,32</sup>. We investigated the pathological correlation between PDCD5 and p53 in Korean gastric cancer samples. Tumour tissues from 78 lymph-node-negative (N0-stage patients having no lymph node metastasis) gastric adenocarcinoma patients were used to generate gene expression profiles using Illumina human bead arrays (HumanHt-12, v3.0, Illumina, San Diego, CA). Pearson correlation coefficient calculations between PDCD5 and p53 in gastric cancer patients’ gene expression profiles revealed a strong positive correlation (r = 0.42; P = 0.00014) (Fig. 7a, upper panel). When we investigated the prognostic power of PDCD5 and p53, neither PDCD5 nor p53 expression levels alone showed significant prognostic discrimination among gastric cancer. However, the combined signature of PDCD5 and p53 showed strong prognostic powers in N0-stage gastric cancer patients (log-rank test P = 0.015) (Fig. 7a, lower left panel). As all of stage 1 and 2a patients survived, we next sub-stratified patients into three groups: stage 1 and 2a patients, stage 2b PDCD5 plus p53 (high) and stage 2b PDCD5 plus p53 (low). Patients showing increased expression of PDCD5 and p53 showed relatively good prognostic outcomes (over 80% 5-year survival rate), while the prognostic outcome of patients showing low expression of PDCD5 and p53 in stage 2b was more than 50% of death rates. We conclude that non-lymph node metastasis gastric cancer patients can be stratified based on disease stage and PDCD5 and p53 signature to show distinct prognostic differences (log-rank test P = 0.000132) (Fig. 7a, lower middle/right panel).

We again verified PDCD5-dependent p53 action in response to genotoxic stress using the wild-type p53-positive gastric cancer cell, AGS. As consistently, ET treatment had negligible effects on HDAC3 cleavage and p53 activation in the absence of PDCD5. Moreover, knockdown of HDAC3 markedly increased p53 stability and activation, while depletion of PDCD5 abrogated this effect (Fig. 7b). Notably, knockdown of HDAC3 further potentiated the effects of PDCD5 restoration on ET-induced p53 activation and HDAC3 cleavage, supporting our notion that PDCD5 promotes p53 acetylation by suppressing HDAC3 function (Fig. 7c). Importantly, reduction of both PDCD5 and p53 levels diminished the effect of ET on DNA damage response more than knockdown of either protein individually (Fig. 7d). Finally, an in vivo tumorigenicity assay using subcutaneous injection of AGS cells into nude mice demonstrated that reduction of either PDCD5 or p53 significantly increased the tumour growth compared with control short hairpin RNA (shRNA) (Supplementary Fig. 16a–c). Strikingly, reduction of both PDCD5 and p53 further enhanced tumour growth and chemoresistance of AGS cells as compared with reduction of the respective protein (Fig. 7e; Supplementary Fig. 16d). Co-knockdown of PDCD5 and HDAC3 significantly increased the chemosensitivity of AGS cells compared with knockdown of PDCD5 alone, indicating a negative action of HDAC3 in p53-mediated genotoxic stress responses (Fig. 7e; Supplementary Fig. 16f). Collectively, these data demonstrate that reduced levels of PDCD5 and p53 enhance in vivo tumorigenic growth of AGS gastric cancer cells and correlate with poor survival in gastric cancer patients.

Discussion

Here, we found that p53 function is reversibly regulated by both HDAC3 and PDCD5 during genotoxic stress response. There has been accumulating evidence that inhibition of HDAC3 enhances p53 acetylation and stability in human cancer and normal cells.<sup>7,8,33</sup> Furthermore, a recent report showed that HDAC3 suppresses p53 activity in coordination with MAGE-A, which confers resistance to chemotherapeutic agents<sup>5</sup>. However, we here observed direct interaction between HDAC3 and p53, and found that HDAC3 deacetylated p53 in vitro. These data suggest that HDAC3 inhibition directly affects p53 acetylation. Furthermore, MAGE-A knockdown had no effect on HDAC3–p53 interaction or HDAC3-mediated inhibition of p53 acetylation and stability. On the basis of these results, it is likely that HDAC3 regulates the acetylation of p53 independently of MAGE-A. We do not exclude the possibility that MAGE-A recruits HDAC3 to inhibit p53 function under certain cellular stresses or a certain type of cells. Further work is necessary to elucidate functional relationships between HDAC3 and MAGE-A in regulating p53 activity.

Although there is evidence for HDAC3 clavage during apoptosis, a detailed understanding of the effects of C-terminal

---

**Figure 5 | PDCD5 promotes p53-dependent apoptosis via selective inhibition of HDAC3.** (a) Overexpression of HDAC3 suppresses the PDCD5-mediated transcription of p53-target genes. Cells were transfected with indicated siRNAs and/or plasmids and treated with either ET or STS. The levels of indicated genes were analysed by real-time PCR. Error bars, s.d. (n = 3). *P < 0.05. (b) PDCD5 promotes p53-dependent apoptosis in a caspase-3-dependent manner. Cells were transfected with indicated plasmids and treated with ET and/or Z-DQMD. Annexin V-positive cells were assessed by flow cytometry. A representative figure of three independent experiments is shown. (c) HDAC3, but not other class I HDACs tested, selectively antagonizes PDCD5-enhanced apoptosis. Annexin V-positive cells were assessed by flow cytometry. Error bars, s.d. (n = 3). *P < 0.05. (d) Knockdown of HDAC3 significantly enhances ET-induced apoptosis. Annexin V-positive cells were assessed by flow cytometry. Error bars, s.d. (n = 3). *P < 0.05; **P < 0.01. (e) PDCD5 is required for ET-induced recruitment of the p53–p300 complex to the promoter region of Bax. Cells were transfected with indicated plasmids and/or shPDCD5 and, then treated with ET. ChIP and re-ChIP assays were performed with the indicated antibodies. Precipitated samples were analysed by real-time PCR, and results are presented as the percentage of input. Error bars, s.d. (n = 3). *P < 0.05; **P < 0.01 versus without ET; ***P < 0.05 versus without ET; ##P < 0.05 versus ET + HA-p53<sup>WT</sup>.
cleavage on HDAC3 function is lacking. In this study, we found that PDCD5-mediated HDAC3 cleavage leads to ubiquitin-dependent proteasomal degradation of HDAC3. PDCD5 knockdown strongly reduced HDAC3 ubiquitination in response to ET treatment. Overexpression of uncleaved HDAC3 inhibited PDCD5-induced p53 acetylation and stabilization more effectively compared with that of wild-type and cleaved (1–391) HDAC3. We showed that PDCD5 competitively inhibited HDAC3–p53 interaction in response to ET treatment, whereas overexpression of the PDCD5E16D mutant, which is defective in its interaction with p53, failed to induce HDAC3 cleavage and p53 activation. These results indicate that PDCD5 and HDAC3 competitively bind to p53 in response to ET treatment, which induces HDAC3 cleavage by caspase-3 and ultimately leads to degradation of the cleaved form of HDAC3.

Previous reports show that PDCD5 is rapidly upregulated and translocated into the nucleus during DNA damage responses; however, the underlying mechanism was unknown. We found that CK2 participated in the positive regulation of PDCD5 function during genotoxic stress responses. We generated phospho-specific PDCD5 antibody, which confirmed that CK2-mediated phosphorylation of PDCD5 at Ser-119 increased concurrently with increasing PDCD5 levels during ET treatment. We showed that CK2 depletion blocked ET-induced PDCD5 stabilization and phosphorylation, and CK2-mediated PDCD5 phosphorylation was required for nuclear translocation of PDCD5. The phospho-mimetic PDCD5 mutant was localized primarily in the nucleus regardless of ET treatment, and its overexpression more efficiently induced HDAC3 cleavage and p53 acetylation more effectively than that of wild-type PDCD5, indicating a positive action of CK2 in the pro-apoptotic function of PDCD5. Accumulating evidence demonstrates that CK2 enhances the stability or nuclear translocation of target proteins via phosphorylation of Ser/Thr residues. Our results indicate that CK2 positively affects PDCD5 function by enhancing both stability and nuclear translocation. Although there is no obvious NLS in PDCD5, we found that phosphorylated PDCD5 is recognized and imported into the nucleus by importin IPO13, which is similar to ERK1/2 and ASF/SF2 (ref. 30). Importantly, knockdown of IPO13 abrogated the nuclear translocation of phospho-mimetic PDCD5S119D mutant, highlighting that IPO13 mediates nuclear translocation of phospho-PDCD5. Further work is necessary to unravel the details of PDCD5 nuclear transport.

On the contrary to previous findings, we found that inhibition of caspase-3, but not caspase-7, completely blocked HDAC3 cleavage by ET and PDCD5 overexpression. These data suggest that caspase-3 is the principal executor for PDCD5-mediated HDAC3 cleavage upon genotoxic stress. One possible scenario is that since caspase-3 is a major effector in human cancer cell lines, it is sufficient for proteolysis of the majority of substrates that are cleaved during the end of apoptosis.

Furthermore, it has been shown that both caspase-3 and caspase-7 commonly cleave certain substrates such as PARP, but exhibit differential activity towards multiple substrates such as Bax, XIAP and co-chaperone p23 (ref. 37). However, we do not exclude the possibility that caspase-7 may be capable of functionally substituting for caspase-3 in situations where both proteases are expressed at similar levels such as Jurkat and NIH3T3 cell lines.

Intriguingly, PDCD5 seems to possess a double-strand DNA-binding domain. This raises the possibility that PDCD5 binds to chromatin with p53 to activate transcription of pro-apoptotic genes. In here, we found that p53 is recruited to p53–RE of Bax and Puma after forming the p53–p300 complex in the presence of PDCD5. Moreover, rescue of PDCD5−/− MEFs with PDCD5WT, but not mutant PDCD5E16D, markedly induced the formation of the p53–p300 complex in the promoter region of Bax and Puma genes. This finding suggests that PDCD5–p53 interaction is required for p53 binding to the target gene promoters, and this association promotes the transcription of pro-apoptotic genes (Supplementary Fig. 16g). Finally, our clinical analyses confirmed a positive correlation between PDCD5 and p53 and gastric cancer patient survival rates. Our data showed that survival rates of stage 2b gastric cancer patients with reduced levels of both PDCD5 and p53 are markedly decreased compared with those patients with reduction of PDCD5 alone. Furthermore, this result is well consistent with that from the mice xenograft assay. This suggests that reduction of PDCD5 and p53 levels may contribute to the early progression of human gastric cancer.

The use of HDAC inhibitors as anticancer treatments has been extensively studied, and several inhibitors are currently in clinical trials. Development of HDACi-based anticancer drugs, however, is limited due to unfavourable toxicities. Though, recent studies in the development of selective HDAC inhibitors have demonstrated that HDAC3-selective inhibitors are promising candidates for anticancer drugs. Thus, future directions for developing clinical applications for HDACi may focus on the use of HDAC subtype-specific inhibitors. A better understanding of individual HDAC function will pave the way for development of prospective HDAC inhibitors as anticancer therapeutics.

**Methods**

**Immunoprecipitation and antibodies.** The antibody against mouse PDCD5 was generated by LabFrontier (Anyang, South Korea) using the synthetic peptide TEKKTGYKFNRRKVMDSEDDADY and used at a 1:500 dilution. The antibody against mouse HDAC3 was generated by LabFrontier using the synthetic peptide CLNVPLRDGIDDQSYHLFQ and YDGDHDNDKESDVEI, respectively, and used at a 1:1,000 dilution. The antibody against phospho-HDAC3S491 was generated by LabFrontier using the synthetic peptide 1114FKRRKVMDPSEDDDDY125 (1:1,000). Antibodies against HDAC1 (sc-78972), HDAC2 (sc-78999), HDAC8 (sc-11405), pro-caspase-8 (sc-7272), pro-caspase-9 (sc-11405), p53 (sc-126 and sc-6243), caspase-3 (sc-7148), caspase-7 (5C-56063S), p21 (sc-397), HA (sc-805), MAGE-2 (sc-130164), HDAC3C-terminal (sc-11417) and pro-caspase-12 (sc-70227) were purchased from Santa Cruz Biotechnology Inc.

**Figure 6** | **PDCD5 is required for genotoxic stress-induced HDAC3 cleavage and p53 activation.** (a) Depletion of PDCD5 abrogated the ET-induced HDAC3 cleavage and p53 activation. MEFs were infected with Ad-Cre or Ad-GFP and then electroporated with Myc-p53 or treated with ET (50 μM, 8 h). Whole-cell lysates were immunoblotted with indicated antibodies. Arrow indicates cleaved HDAC3. (b) PDCD5 promotes ET-induced p53 activation and HDAC3 cleavage. (c) Restoration of PDCD5 into PDCD5−/− MEFs induces the recruitment of the p53–p300 complex to the promoter region of Bax. ChIP assays were performed with the indicated antibodies. Error bars, s.d. (n = 3). *P < 0.05, **P < 0.01. (d) Both PDCD5 and p53 are mutually required for ET-induced activation of apoptosis. Stable shPDCD5-expressing p53−/− MEFs were electroporated with indicated plasmids and treated with ET, lysed and then analysed by immunoblotting. (e) Knockdown of HDAC3 rescues the suppression of p53 caused by depletion of PDCD5. (f) Negative effect of cleavage at Asp-391 on the anti-apoptotic function of HDAC3. Cell lysates were analysed by immunoblotting. (g) Ablation of HDAC5 abolishes the genotoxic stress response in vivo. Mice were injected with ET (10 mg kg−1) for the indicated days. Adenovirus expressing GFP or Cre recombinase was injected in mice 6 days before ET injection, as indicated. Tissues from individual livers were harvested and processed for western blotting. Total RNA was isolated from individual livers, and qRT-PCR was performed for the indicated genes. Error bars, s.d. (n = 8). *P < 0.05 versus without ET, **P < 0.05 versus ET (2 days).
Antibody against PDCD5 (12456-1-AP) was purchased from Proteintech Group Inc. (Chicago, IL, USA). FLAG (F3165) and β-actin (A5441) antibodies were obtained from Sigma-Aldrich. Myc (#2278S), acetyl-p53K379 (#2570), acetyl-p53K382 (#2525S) and active-caspase-3 (#96615) antibodies were purchased from Cell Signaling (Beverly, MA, USA). Tubulin (05-829), GAPDH (CB1001) and p300 (N446) antibodies were obtained from Millipore (Billerica, MA, USA). PARP-1 (51-6639GR) antibody was purchased from BD Transduction Laboratories (Lexington, KY, USA). Bax (1063-1) and acetyl-p53K373 antibodies were purchased from Abcam.

**Figure a**

- **PDCD5**
  - ET
  - Ad-GFP
  - Ad-Cre
  - ET
  - Ad-GFP
  - Ad-Cre

**Figure b**

- **PDCD5**
  - ET
  - HA-PDCD5
  - HA-PDCD5
  - ET
  - HA-PDCD5
  - HA-PDCD5

**Figure c**

- ChIP assay (PDCD5
  - Control
  - Control
  - HA-PDCD5
  - HA-PDCD5

**Figure d**

- **PDCD5**
  - ET
  - Myc-p53
  - HA-HDAC3
  - HA-HDAC3

**Figure e**

- **PDCD5**
  - ET
  - shCon
  - shHDAC3
  - HA-PDCD5
  - HA-PDCD5

**Figure f**

- **PDCD5**
  - ET
  - HA-PDCD5
  - HA-PDCD5

**Figure g**

- **PDCD5**
  - ET
  - Ad-GFP
  - Ad-Cre
  - ET
  - Ad-GFP
  - Ad-Cre
versus shPDCD5 with ET. Error bars indicate s.d. (treatment with ET (10 mg kg⁻¹) were transfected with siHDAC3 and/or shPDCD5 as indicated, and treated with or without ET. DNA damage of cells was determined by the TUNEL assay. Error bars, indicated antibodies. (100 mm³) were selected for treatment with etoposide (10 mg kg⁻¹) (Dr B. Vogelstein, Johns Hopkins University) and human p53⁺/o⁺ cell line of the Eberichideri col strain BL21 (DE3) with 0.5 mM isopropyl-β-D-thiogalactoside for 2 h, and then isolated using Glutathione Sepharose 4B beads (Peptron, Korea) according to the manufacturer’s instructions. All constructs were verified by DNA sequencing.

Generation of PDCD5flex/flox mice and MEFs. Conditional targeting strategy of pdcd5 was carried out by the insertion of a loxP site between exon 2 and exon 3. An additional site was inserted upstream of exon 4 (Supplementary Fig. 13). Primers used for genotyping are given in Supplemental Table 4. The wild-type and PDCD5flex/– MEFs were generated in the presence of the FII-transfected in the Eberichideri col strain BL21 (DE3).
**Gene expression data.** Experiments and analysis for 78 samples from the YUSH data set were conducted in the Yonsei University Severance Hospital. All specimens from patients were collected and archived under the standard protocols with codified patient identification information. The need for informed consent for the gene expression analysis was waived by the institutional review board of Severance Hospital Yonsei University Health System, as the current study was considered a retrospective review of anonymized clinical data. The information on clinic-pathological characteristics of cancer patients was described in Supplementary.
Table 5. Gene expression profiles were generated by hybridizing labelled cRNAs to Illumina human bead arrays (HumanHT-12, v3.0) containing 48,803 gene features. Total RNA was extracted from the freshly frozen tissue using a mirVana RNA isolation labeling kit (Ambion, Inc. Grand Island, NY, USA). Total RNA (500 ng) was used for labelling and hybridization, according to the manufacturer’s protocol. After the bead chips were scanned with an Illumina BeadArray Scanner, the microarray data were normalized with a quartile normalization method in the Linear Models for Microarray Data (LIMMA) package in the R language environment. Kaplan–Meier plots and log-rank tests were used to estimate the prognostic differences of categorized patient groups.

Dualink in situ proximity ligation assay (PLA). Dualink in situ PLA analysis was performed according to the manufacturer’s instructions (OLink Biosciences, Uppsala, Sweden). In short, paraformaldehyde-fixed cells were washed with PBS, incubated for 15 min in 1.5% hydrogen peroxide, washed and blocked with blocking solution. Primary rabbit antibody was applied, and the cells were incubated with PLUS and MINUS secondary PLA probes against rabbit IgG only or against both rabbit and mouse IgG. After the sample was incubated, hybridization, ligation and amplification steps were performed. Samples were mounted with Dualink mounting medium, and then examined using a Zeiss LSM700 confocal microscope (Carl Zeiss, Oberkochen, Germany).

HDAC activity assay. Briefly, in the standard assay, 5 μg histone H4 tail peptides were incubated with 0.25 μCi of [3H] acetyl coenzyme A (Amersham) in 20 μl reaction buffer containing 50 mM Tris (pH 8.0), 5% glycerol, 0.1 mM EDTA, 50 mM KCl, 1 mM dithiothreitol (DTT), 1 mM phenylmethylsulphonyl fluoride and 10 mM sodium butyrate at 30 °C for 2 h. Immunoprecipitated HDAC3 samples were incubated with [3H]-acetate-labelled H4 histone in 150 μl of reaction buffer (20 mM Tris at pH 8.0, 150 mM NaCl and 10% glycerol) overnight at room temperature. Reactions were quenched with 1 M HCl and 0.16 M acetic acid (50 μl in each sample). Released [3H]-acetic acid was extracted with 600 μl ethyl acetate by vortexing and centrifugation (1 min at 9,500 g). Ethyl acetate supernatants (300 μl from each sample) were quantified by scintillation counting. The results are shown as mean ± s.d. calculated from three independent experiments.

RNA isolation and quantitative RT–PCR. PCR primers for qRT–PCR are described in Supplementary Table 4. The concentration of complementary DNA was normalized using GAPDH. QPCR analysis and quantification was performed using SYBR Green PCR master mix reagents and an ABI Prism 7700 sequence detection system (Applied Biosystems, Carlsbad, CA, USA). All reactions were performed in triplicate. Relative expression levels and s.d. were calculated using the comparative method. The results are shown as mean ± s.d. calculated from three independent experiments.

Chromatin immunoprecipitation (ChIP) assay. Briefly, ~2 × 10⁸ cells in 100-mm dishes were first treated with PBS containing 1% formaldehyde for 10 min, washed twice with cold PBS and then incubated with 100 mM Tris (pH 9.4) and 10 mM DTT at 37 °C for 15 min. The cells were then rinsed twice in PBS and resuspended in 600 μl of SOA (10 mM Hepes (pH 7.9), 0.5% NP-40, 1.5 M MgCl₂, 10 mM KCl and 0.5 mM DTT) by pipetting. After a short spin, the pellets were resuspended in SOB (20 mM Hepes (pH 7.9), 25% glycerol, 0.5% NP-40, 0.42 M NaCl, 1.5 mM MgCl₂ and 0.2 mM EDTA) containing protease inhibitors followed by vigorous pipetting to extract proteins. After centrifugation at 13,000 r.p.m. for 30 min, the nuclear pellets were resuspended in immunoprecipitation buffer (1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl (pH 8.0), 150 mM NaCl and protease inhibitors) and sonicated to break chromatin into fragments of 0.5–1 kb average length. The ChIP assays were then preformed with the indicated antibodies essentially as described, but without SDS in all buffers. Primers were used for ChIP assays described in Supplementary Table 4. All reactions were normalized relative to input activities and are presented as mean ± s.d. of three independent experiments. The results are shown as percentage of input.

TUNEL assay. For the detection of apoptosis in cells, DNA fragmentation was evaluated by the TdT-mediated dUTP nick end labelling (TUNEL) assay using an HT Titer TACS Assay Kit (Cat No. 4822-96-K, Trevigen, Gaithersburg, MD, USA) according to the manufacturer’s instructions. Briefly, cells were fixed with a 3.7% buffered formaldehyde solution for 7 min, washed with PBS, permeabilized with 0.1% Triton X-100 for 20 min and then washed twice with PBS. Samples were digested with proteinase K for 15 min, and then quenched with 3% hydrogen peroxide. Samples were then washed with distilled water, labelled with deoxyoxanucleotidyl transferase at 37 °C for 90 min and then treated with stop buffer. The cells were incubated with TACS-Sapphire substrate, and the colorimetric reaction was stopped with 0.2 N HCl at 37 °C for 30 min. Absorbance was measured with an ELISA reader at 450 nm. The results are shown as mean ± s.d. calculated from three independent experiments.

Annexin V-FITC staining. To assess the extent of apoptosis after DNA damage, cells were stained with both Annexin V-fluorescein isothiocyanate (FITC) and propidium iodide (PI). Cells were resuspended in 100 μl of binding buffer (10 mM HEPES, pH 7.4, 140 mM NaCl, 2.5 mM CaCl₂ and 0.5 mM MgCl₂) that encoded the Annexin V-FITC as 7-amino-5-methyl-4-isothiocyanatofluorescein, ethyl ester (AMUI, Texas) at a 1:100 dilution in 4% paraformaldehyde for 30 min at 4 °C. The Alexa Fluor 647-conjugated annexin V-FITC was then added at a 1:500 dilution to PBS. After incubation for 15 min, the samples were washed with ice-cold PBS and immediately analyzed by a BD FACSCalibur™ flow cytometer. Cells were gated as live (Annexin V−/PI−), early apoptotic (Annexin V+/PI−), late apoptotic (Annexin V+/PI+) and necrotic (Annexin V−/PI+) using the Multi-Cycle™ Annexin V-FITC Apoptosis Detection System (Lonza, Walkersville, MD, USA).

DNA isolation. Genomic DNA was isolated from cultured cells using the QIAamp DNA minikit (Qiagen, Hilden, Germany). DNA was dissolved in 20 μl of water and quantified spectrophotometrically.

Statistical analysis. Statistical analyses were performed using a Student’s t-test with Bonferroni correction for multiple comparisons. A P value of less than 0.05 was considered statistically significant.

References
1. Vazquez, A., Bond, E. E., Levine, A. J. & Bond, G. L. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat. Rev. Drug Discov. 7, 979–987 (2008).
2. Bode, A. M. & Dong, Z. Post-translational modification of p53 in tumorigenesis. Nat. Rev. Cancer 4, 793–805 (2004).
3. Olner, J. D. et al. Oncoprotein MDM2 conceals the activation domain of p53. Nature 362, 857–860 (1993).
4. Ito, A. et al. MDM2-HDAC1-mediated decetylation of p53 is required for its degradation. EMBO J. 21, 2224–2235 (2002).
5. Narita, N. et al. Suppression of histone deacetylase 3 (HDAC3) enhances apoptosis induced by paclitaxel in human maxillary carcinoma cells in vitro and in vivo. Biochem. Biophys. Res. Commun. 396, 310–316 (2010).
6. Zeng, L. et al. HDAC3 is crucial in shear- and VEGF-induced stem cell differentiation toward endothelial cells. J. Cell Biol. 174, 1059–1069 (2006).
7. Mroz, M. et al. MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc. Natl Acad. Sci. USA 103, 11160–11165 (2006).
8. Kim, Y. et al. miR-326-Histone deacetylase-3 feedback loop regulates the invasion and tumorigenic and angiogenic response to anti-cancer drugs. J. Biol. Chem. 289, 28019–28039 (2014).
12. Escartin, F. et al. Cleavage and cytoplasmic relocation of histone deacetylase 3 are important for apoptosis progression. Mol. Cell. Biol. 27, 554–567 (2007).
13. Pickard, C. M., Wenzig, M., Specht, T., Saeger, H. D. & Grutzmann, R. Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. Neoplasia 6, 744–750 (2004).
14. Liu, H. et al. TFAr19, a novel apoptosis-related gene cloned from human leukemia cell line TF-1, could enhance apoptosis of some tumor cells induced by growth factor withdrawal. Biochem. Biophys. Res. Commun. 254, 203–210 (1999).
15. Dobson, A. T. et al. The unique transcriptome through day 3 of human preimplantation development. Hum. Mol. Genet. 13, 1461–1470 (2004).
16. Li, H. et al. Reduced expression of PDCD5 is associated with high-grade astrocytic gliomas. Oncol. Rep. 20, 573–579 (2008).
17. Spinola, M. et al. Association of the PDCD5 locus with lung cancer risk and prognosis in patients with non-small cell lung cancer. J. Clin. Oncol. 24, 1672–1678 (2006).
18. Yang, Y. H. et al. Expression of programmed cell death 5 gene involves in regulation of apoptosis in gastric tumor cells. Apoptosis 11, 993–1001 (2006).
19. Xu, H. et al. Transfection of PDCD5 effect on the biological behavior of tumor cells and sensitized gastric cancer cells to cisplatin-induced apoptosis. Life Sci. 71, 1771–1778 (2002).
20. Yin, A., Jiang, Y., Zhang, Y., Zhao, J. & Luo, H. Transfection of PDCD5 sensitizes colorectal cancer cells to cisplatin-induced apoptosis in vitro and in vivo. Eur. J. Pharmacol. 649, 120–126 (2010).
21. Xu, L. et al. PDCD5 interacts with Tip60 and functions as a coactivator in acetyltransferase activity and DNA damage-induced apoptosis. Neoplasia 11, 345–354 (2009).
22. Wang, Y. et al. An alternative form of paraptosis-like cell death, triggered by TAJ/TROY and enhanced by PDCD5 overexpression. J. Cell Sci. 117, 1525–1532 (2004).
23. Rui, M., Chen, Y., Zhang, Y. & Ma, D. Transfer of anti-TFAR19 monoclonal antibody into HeLa cells by in situ electroporation can inhibit the apoptosis. Apoptosis 11, 1847–1856 (2012).
24. Xu, L. et al. PDCD5 interacts with p53 and functions as a positive regulator in the p53 pathway. Apoptosis 17, 1235–1245 (2012).
25. Choi, H. K. et al. Reversible SUMOylation of TBL1-TBLR1 regulates beta-catenin-mediated Wnt signaling. Mol. Cell 43, 203–216 (2011).
26. Li, J. et al. Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3. EMBO J. 19, 4342–4350 (2000).
27. Tang, Y., Zhao, W., Chen, Y., Zhao, Y. & Gu, W. Acetylation is indispensable for p53 activation. Cell 133, 612–626 (2008).
28. Essers, P. B. et al. The von Hippel-Lindau tumor suppressor regulates programmed cell death 5-mediated degradation of Mdm2. Oncogene 34, 771–779 (2014).
29. Salvi, M. et al. Programmed cell death protein 5 (PDCD5) is phosphorylated by CK2 in vitro and in 293T cells. Biochem. Biophys. Res. Commun. 387, 606–610 (2009).
30. Nardozzi, J. D., Lott, K. & Cingolani, G. Phosphorylation meets nuclear import: CK2-dependent phosphorylation determines cellular localization and stability of ataxin-3. Hum. Mol. Genet. 18, 3334–3343 (2009).
31. Marchler-Bauer, A. et al. CDD: conserved domains and protein three-dimensional structure. Nucleic Acids Res. 41, D348–D352 (2013).
32. Zhang, X. et al. Clinical and prognostic significance of lost or decreased PDCD5 expression in human epithelial ovarian carcinomas. Oncol. Rep. 25, 353–358 (2011).
33. Zhang, F., Shi, Y., Wang, L. & Srinivas, S. Role of HDAC3 on p53 expression and apoptosis in T cells of patients with multiple sclerosis. PLoS ONE 6, e16795 (2011).
34. Calvert, M. E. et al. Phosphorylation by casein kinase 2 regulates Nap1 localization and function. Mol. Cell. Biol. 28, 1313–1325 (2008).
35. Mueller, T. et al. CK2-dependent phosphorylation determines cellular localization and stability of ataxin-3. Hum. Mol. Genet. 18, 3334–3343 (2009).
36. Trembly, J. H., Wang, G., Unger, G., Slaton, J. & Ahmed, K. Protein kinase CK2 in health and disease: CK2: a key player in cancer biology. Cell. Mol. Life Sci. 66, 1858–1867 (2009).
37. Walsh, J. G. et al. Executioner caspase-3 and caspase-7 are functionally distinct proteases. Proc. Natl Acad. Sci. USA 105, 12815–12819 (2008).
38. Kirschaum, M. et al. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. J. Clin. Oncol. 29, 1198–1203 (2011).
39. Minami, J. et al. Histone deacetylase 3 (HDAC3) as a novel therapeutic target in multiple myeloma. Leukemia. 28, 680–689 (2013).
40. Suzuki, T. et al. Identification of highly selective and potent histone deacetylase 3 inhibitors using click chemistry-based combinatorial fragment assembly. PLoS ONE 8, e68669 (2013).
41. Wenger, C. D., Phanstiel, D. H., Lee, M. V., Bailey, D. J. & Coon, J. J. COMPASS: a suite of pre- and post-processing proteomics software tools for OMSA. Proteomics 11, 1064–1074 (2011).
42. Bolstad, B. M., Irizarry, R. A., Astrand, M. & Speed, T. P. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19, 185–193 (2003).
43. Lee, Y. J. et al. Nuclear receptor PPARgamma-regulated monoacylglycerol O-acyltransferase 1 (MGAT1) expression is responsible for the lipid accumulation in diet-induced hepatic steatosis. Proc. Natl Acad. Sci. USA 109, 13656–13661 (2012).
44. Luo, J. et al. A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat. Protoc. 2, 1236–1247 (2007).

Acknowledgements

This work was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2012R1A6A3A04041010) (H.-K.C.), and the NRF grant funded by the Korea Government (MSIP) (Nos NRF-2012R1A2A1A01001862 and NRF-2011-0030086) (H.-G.Y.).

Author contributions

H.-K.C., Y.C. and E.S.P. designed and performed the experiments. S.-Y.P. and M.-H.J. performed mice experiments. P.C.W.L. performed the LC–MS/MS experiment. S.-H.L. and J.-W.J. provided reagents and conceptual advice. K.-C.C. and H.-G.Y. interpreted data and prepared the manuscript.

Additional information

Supplementary Information accompanies this paper at http://www.nature.com/naturecommunications

Competing financial interests: The authors declare no competing financial interests.

Reprints and permission information is available online at http://npg.nature.com/reprintsandpermissions/

How to cite this article: Choi, H.-K. et al. Programmed cell death 5 mediates HDAC3 decay to promote genotoxic stress response. Nat. Commun. 6:7390 doi: 10.1038/ncomms8390 (2015).
Corrigendum: Programmed cell death 5 mediates HDAC3 decay to promote genotoxic stress response

Hyo-Kyoung Choi, Youngsok Choi, Eun Sung Park, Soo-Yeon Park, Seung-Hyun Lee, Jaesung Seo, Mi-Hyeon Jeong, Jae-Wook Jeong, Jae-Ho Cheong, Peter C.W. Lee, Kyung-Chul Choi & Ho-Geun Yoon

Nature Communications 6:7390 doi: 10.1038/ncomms8390 (2015); Published 16 Jun 2015; Updated 21 Aug 2015.

The original version of this Article contained a typographical error in the spelling of the author Jae-Ho Cheong, which was incorrectly given as Jae-Ho Jeong. This has now been corrected in both the PDF and HTML versions of the Article.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/